RT Journal Article
SR Electronic
T1 A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.20.21255810
DO 10.1101/2021.04.20.21255810
A1 Stephen A. Chitty
A1 Sarah Mobbs
A1 Brian S. Rifkin
A1 Steven W. Stogner
A1 Michael S. Lewis
A1 Jaime Betancourt
A1 Jeffrey DellaVolpe
A1 Fadi Abouzahr
A1 Andrew M. Wilhelm
A1 Harold M. Szerlip
A1 Robert M. Gaeta
A1 Ian Rivera
A1 James D. Oliver
A1 Stephen W. Olson
A1 Subrata Debnath
A1 Sean P. Barnett
A1 Amay Parikh
A1 Robert J. Walter
A1 Mai T. Nguyen
A1 Breandan Sullivan
A1 Karl C. Alcover
A1 Ian J. Stewart
A1 Kathleen P. Pratt
A1 Kumar Sharma
A1 Kevin K. Chung
A1 for the PURIFY INVESTIGATORS
YR 2021
UL http://medrxiv.org/content/early/2021/04/23/2021.04.20.21255810.abstract
AB Objective The Seraph®100 Microbind Affinity Blood Filter® (Seraph 100) is an extracorporeal medical countermeasure that can remove many pathogens from blood, including the SARS-CoV-2 virus. The aim of this study was to evaluate safety and efficacy of Seraph 100 treatment for severe coronavirus disease 2019 (COVID-19).Design Multicenter retrospective observational cohort study.Setting Intensive care units across four of thirteen participating sites who have completed data extraction.Patients Critically ill COVID-19 patients treated with Seraph 100 under an Emergency Use Authorization (n=53) and historical control patients who met criteria for treatment (n=46).Intervention Extracorporeal treatment with the Seraph 100 filter.Measurements and Main Results At baseline, the median age was 61 years, 72.7% were male, and 59.6% required mechanical ventilation. The groups were matched in terms of sex, race/ethnicity, body mass index, APACHE II score, need for mechanical ventilation, and other COVID-19 treatments. However, patients in the Seraph 100 group were younger with a median age of 61 years (IQR 42-65) compared to controls who had a median age of 64 (IQR 56-68, p=0.036). The Seraph 100 group also had a lower median Charlson comorbidity index (2, IQR 0-3) compared to control patients (3, IQR 2-4, p=0.006). Mortality was lower in the Seraph 100 treated group compared to the historical controls (37.7% vs 67.4%, respectively, p=0.003). Multivariable logistic regression analysis yielded an odds ratio of 0.27 (95% confidence interval 0.09-0.79, p=0.016). Of the 53 patients treated with Seraph 100, only 1 patient experienced a serious adverse event (transient hypotension at the start of the treatment which required a brief period of vasopressor support).Conclusions These data suggest that broad spectrum, pathogen agnostic, extracorporeal blood purification technologies can be safely and effectively deployed to meet new pathogen threats as an adjunct to standard treatments while awaiting the development of directed pharmacologic therapies and/or vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04606498Funding StatementThis work was supported by awards from the Defense Health Program and the CARES Act (HU00012020067).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An Observational Study (PURIFY-OBS-1) was reviewed and approved by the Advarra institutional review board in accordance with all applicable Federal regulations governing human research protections (Clinicaltirals.gov Identifier NCT04606498).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be available once final report is published upon request.